scholarly journals Coronavirus Disease 2019: Clinical Review

2020 ◽  
Vol 33 (7-8) ◽  
pp. 505 ◽  
Author(s):  
Cristina Carvalho Gouveia ◽  
Luís Campos

Introduction: In December 2019, an outbreak of pneumonia caused by a novel coronavirus occurred in Wuhan, the capital of Central China’s Hubei Province and has been declared a public health emergency of international concern by the World Health Organization since January 2020.Material and Methods: A comprehensive search using the PubMed database was carried out to summarize the latest published information about the epidemiology, definition, pathogenesis, clinical characteristics, treatment options, prognosis and prevention of coronavirus disease 2019.Discussion: This new strain of coronavirus, named severe acute respiratory syndrome coronavirus 2, enters human cells that express angiotensin-converting enzyme II receptors, which exist in the respiratory, gastrointestinal and genitourinary tracts and heart, causing coronavirus disease. Transmission occurs essentially through the respiratory tract and the main symptoms are fever, cough and dyspnea. Diagnosis is based on epidemiological, clinical and imaging features and confirmed by nucleic acid testing.Conclusion: Despite intensive research, the exact origin of the virus and pathophysiology of coronavirus disease is not yet completely known, and clinically approved vaccines and drugs that target severe acute respiratory syndrome coronavirus 2 are lacking.

Author(s):  
Lara Bittmann

On December 31, 2019, WHO was informed of cases of pneumonia of unknown cause in Wuhan City, China. A novel coronavirus was identified as the cause by Chinese authorities on January 7, 2020 and was provisionally named "2019-nCoV". This new Coronavirus causes a clinical picture which has received now the name COVID-19. The virus has spread subsequently worldwide and was explained on the 11th of March, 2020 by the World Health Organization to the pandemic.


2020 ◽  
Vol 8 ◽  
Author(s):  
Bapi Gorain ◽  
Hira Choudhury ◽  
Nagashekhara Molugulu ◽  
Rajani B. Athawale ◽  
Prashant Kesharwani

Sudden outbreak of a new pathogen in numbers of pneumonic patients in Wuhan province during December 2019 has threatened the world population within a short period of its occurrence. This respiratory tract–isolated pathogen was initially named as novel coronavirus 2019 (nCoV-2019), but later termed as SARS-CoV-2. The rapid spreading of this infectious disease received the label of pandemic by the World Health Organization within 4 months of its occurrence, which still seeks continuous attention of the researchers to prevent the spread and for cure of the infected patients. The propagation of the disease has been recorded in 215 countries, with more than 25.5 million cases and a death toll of more than 0.85 million. Several measures are taken to control the disease transmission, and researchers are actively engaged in finding suitable therapeutics to effectively control the disease to minimize the mortality and morbidity rates. Several existing potential candidates were explored in the prevention and treatment of worsening condition of COVID-19 patients; however, none of the formulation has been approved for the treatment but used under medical supervision. In this article, a focus has been made to highlight on current epidemiology on the COVID-19 infection, clinical features, diagnosis, and transmission, with special emphasis on treatment measures of the disease at different stages of clinical research and the global economic influence due to this pandemic situation. Progress in the development on vaccine against COVID-19 has also been explored as important measures to immunize people. Moreover, this article is expected to provide information to the researchers, who are constantly combating in the management against this outbreak.


Author(s):  
Roberto Lo Giudice

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a novel coronavirus first identified in Wuhan, China, and the etiological agent of Coronavirus Disease-2019 (COVID-19). This infection spreads mainly through direct contact with Flügge micro droplets or core droplets that remain suspended as aerosol. Moreover, it has been reported that infected subjects, both with and without clinical signs of COVID-19, can transmit the virus. Since the infection typically enters through mouth, nose, and eyes, dentistry is one of the medical practices at highest risk of infection due to the frequent production of aerosol and the constant presence of saliva. The World Health Organization (WHO) has suggested that only emergency/urgent procedures should be performed during the coronavirus outbreak. Considering the virus’ route of transmission, a specific protocol should be applied to reduce the risk of infection in addition to measures that prevent the spread of infection from a patient to another person or medical tools and equipment (cross-infection). This protocol should be implemented by modifying both patient management and clinical practice, introducing particular devices and organizational practices. This paper aims to discuss and suggest the most appropriate procedures in every aspect of dental practice to reduce infection risk.


PeerJ ◽  
2020 ◽  
Vol 8 ◽  
pp. e9725 ◽  
Author(s):  
Tingting Hu ◽  
Ying Liu ◽  
Mingyi Zhao ◽  
Quan Zhuang ◽  
Linyong Xu ◽  
...  

In mid-December 2019, a novel atypical pneumonia broke out in Wuhan, Hubei Province, China and was caused by a newly identified coronavirus, initially termed 2019 Novel Coronavirus and subsequently severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of 19 May 2020, a total of 4,731,458 individuals were reported as infected with SARS-CoV-2 among 213 countries, areas or territories with recorded cases, and the overall case-fatality rate was 6.6% (316,169 deaths among 4,731,458 recorded cases), according to the World Health Organization. Studies have shown that SARS-CoV-2 is notably similar to (severe acute respiratory syndrome coronavirus) SARS-CoV that emerged in 2002–2003 and Middle East respiratory syndrome coronavirus (MERS-CoV) that spread during 2012, and these viruses all contributed to global pandemics. The ability of SARS-CoV-2 to rapidly spread a pneumonia-like disease from Hubei Province, China, throughout the world has provoked widespread concern. The main symptoms of coronavirus disease 2019 (COVID-19) include fever, cough, myalgia, fatigue and lower respiratory signs. At present, nucleic acid tests are widely recommended as the optimal method for detecting SARS-CoV-2. However, obstacles remain, including the global shortage of testing kits and the presentation of false negatives. Experts suggest that almost everyone in China is susceptible to SARS-CoV-2 infection, and to date, there are no effective treatments. In light of the references published, this review demonstrates the biological features, spread, diagnosis and treatment of SARS-CoV-2 as a whole and aims to analyse the similarities and differences among SARS-CoV-2, SARS-CoV and MERS-CoV to provide new ideas and suggestions for prevention, diagnosis and clinical treatment.


2021 ◽  
Vol 5 (1) ◽  
pp. 44-58
Author(s):  
Silvia Rizki Syah Putri ◽  
Cesa Septiana Pratiwi ◽  
Herlin Fitriani Kurniawati ◽  
Luluk Rosida

World Health Organization (WHO) menyebut coronavirus disease yang ditemukan pertama kali di Wuhan dengan novel coronavirus 2019 (2019-nCoV) yang disebabkan oleh virus Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Ibu hamil, bersalin, nifas dan bayi baru lahir juga merupakan sasaran yang rentan terhadap infeksi Covid-19 (Kemenkes RI, 2020).Tujuan dari Rapid Review ini adalah untuk mengetahui ibu hamil, bersalin dan nifas yang terkonfirmasi Covid-19.Dari 12 Artikel yang didapatkan ibu hamil, bersalin dan nifas terkonfirmasi  Covid-19 dilihat dari aspek biologi, aspek psikologi dan aspek sosial. Tetapi masih diperlukan untuk mengivestigasi mendalam terkait pengalaman ibu hamil, bersalin dan nifas terkonfirmasi Covid-19.


2020 ◽  
Vol 10 (3-s) ◽  
pp. 286-294 ◽  
Author(s):  
Shabir Ahmad Bhat ◽  
Shameem Ahmad Rather ◽  
Arsheed Iqbal ◽  
Haider Ali Qureshi ◽  
Naquibul Islam

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is highly infectious, spreading swiftly from man to man which has not been previously recognized in humans. World Health Organization (WHO) on February 11, 2020 named the infection as COVID-19 as an acronym for ‘coronavirus disease-2019’ and on March 11, 2020 declared the outbreak as pandemic. It affects all the people without discrimination, however, older, immune compromised are more susceptible. The virus chiefly spread through droplet infection from infected person to healthy one by coughing, sneezing or with infected hands when touched to eyes, nose or mouth. Symptoms of the infection range from mild to severe ones. In severe cases (approx. 14% of cases) fever typically of high grade (104oF), breathlessness, pneumonia and severe acute respiratory syndrome may appear. So far no specific treatment or vaccine for novel coronavirus-2019 is there. From the past and recent past experiences we have learnt that herbal medicines have proven beneficial against various dreadful viral infections. Assessment of immune enhancing herbs in this paper may definitely be helpful for the body to fight COVID-19 infection. Keywords:   Severe acute respiratory syndrome coronavirus-2, COVID-19, Pneumonia, Immune, Herbs


2020 ◽  
Author(s):  
Mujib Ullah

Coronavirus also called SARS-COV-2 showed highly pathogenic, caused severe or even life-threatening diseases, and still transmitted from person-to-person. Given fast evolution of the COVID-19 outbreak, world health organization declared its outbreak as pandemic. Until now, no drugs or biologics have been proven to be effective for the prevention or treatment of COVID-19. Mainstream medicine has little in its arsenal for viral diseases. Some promising agents are selectively RNA inhibitors, an antimalarial agent, an HIV protease inhibitor, and an influenza viral neuraminidase inhibitor, which showed good clinical efficacy in treating COVID-19.


Medicina ◽  
2020 ◽  
Vol 56 (10) ◽  
pp. 506 ◽  
Author(s):  
Pierpaolo Di Micco ◽  
Vincenzo Russo ◽  
Corrado Lodigiani

Asreported by the World Health Organization, a novel coronavirus (COVID-19) was identified as the causative virus of new viral pneumonia of unknown etiology by Chinese authorities on 7 January 2020. The virus was named COVID-19 and because of its ability to cause severe acute respiratory syndrome (i.e., SARS) this infection has also been defined as SARS-CoV2.Furthermore, an association between COVID-19 infection and venous thromboembolism has been reported in several series around the world.For this reason, methods used to improve diagnostic tools, pharmacological thromboprophylaxis and type of anticoagulants are discussed in this expert opinion.


2021 ◽  
pp. 1-3
Author(s):  
Rajvi Dave ◽  
Bhavesh Jarwani ◽  
Sanket Nandani ◽  
Tirth Patel

BACKGROUND : Coronavirus disease 2019(COVID 19) is an illness which is associated with the novel coronavirus known as severe acute respiratory syndrome coronavirus 2(SARS-CoV -2).On December 2019, Wuhan City in China, became the epicenter of this pandemic. On March 17 2020 Ahmedabad reported its first positive case. On January 2020, Chinese scientists identified this as a novel coronavirus, temporarily labelled as, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. Its name was then changed to coronavirus disease 2019 (COVID-19) by the World Health Organization in February 2020 as the disease spread worldwide [2]. COVID 19 pandemic has posed a huge threat to global public health .The clinical features of COVID-19 are very diverse, ranging from asymptomatic state to acute respiratory distress syndrome and multi organ dysfunction. The common clinical features include fever, cough, sore throat, headache, fatigue, headache, myalgia and breathlessness. Emergency workers carry a huge responsibility in this pandemic. We have to provide early triage and management of patients with suspected or confirmed infection in which inflammatory markers play an important role. More importantly we have to try to prevent the spread of infection and also be prepared to tackle such large footfalls in ED


2003 ◽  
Vol 7 (15) ◽  
Author(s):  

Several articles on the identification of a novel coronavirus thought to have a role in causing severe acute respiratory syndrome (SARS) have been given early online publication this week (1-5), and the World Health Organization (WHO) has published an interim report from the WHO team of experts currently investigating the outbreak in China (7).


Sign in / Sign up

Export Citation Format

Share Document